A new approach to psychiatric drug approval in Europe.
Corrado Barbui and Irene Bighelli question the current rules governing registration of new medicines in Europe, using the example of psychiatric drugs, and argue that the concept of absolute efficacy should be replaced by the concept of added value whereby evidence from studies comparing a new produ...
Guardado en:
Autores principales: | Corrado Barbui, Irene Bighelli |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b8e696bbe06c4bc6a133b42fe091c518 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe.
por: Emanuel Raschi, et al.
Publicado: (2013) -
Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs
por: Shuo Gu, et al.
Publicado: (2018) -
Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications
por: Isaac V. Cohen, et al.
Publicado: (2017) -
An open science pathway for drug marketing authorization-Registered drug approval.
por: Florian Naudet, et al.
Publicado: (2021) -
Europe needs a central, transparent, and evidence-based approval process for behavioural prevention interventions.
por: Fabrizio Faggiano, et al.
Publicado: (2014)